Neuraxis (NRXS) Other Non-Current Liabilities (2022 - 2026)
Neuraxis (NRXS) posted Other Non-Current Liabilities of $48306.0 for Q1 2026, up 187.54% sequentially from $16800.0 in Q4 2025, and up 558.57% YoY from $7335.0 in Q1 2025.
Neuraxis (NRXS) Other Non-Current Liabilities (2022 - 2026) Analysis & Trends
Neuraxis has reported Other Non-Current Liabilities for 5 years, with the latest figure at $48306.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities rose 558.57% year-over-year to $48306.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48306.0 (up 558.57% YoY) and the FY2025 annual result came in at $16800.0, up 83.29% from the prior year.
- Other Non-Current Liabilities rose to $48306.0 in Q1 2026 per NRXS's latest filing, from $16800.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $2.3 million in Q2 2023 and troughed at $7335.0 in Q1 2025.
- A 5-year average of $528730.5 and a median of $16800.0 in 2025 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Liabilities slumped 99.63% in 2023, then soared 646.18% in 2025.
- Over 5 years, Other Non-Current Liabilities stood at $2.2 million in 2022, then plunged by 99.63% to $8225.0 in 2023, then rose by 11.44% to $9166.0 in 2024, then jumped by 83.29% to $16800.0 in 2025, then soared by 187.54% to $48306.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $48306.0, $16800.0, and $124306.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 45,857.00 |
| Mar 31, 2026 | 48,306.00 |
| Dec 31, 2025 | 16,800.00 |
| Sep 30, 2025 | 124,306.00 |
| Jun 30, 2025 | 7,454.00 |
| Mar 31, 2025 | 7,335.00 |
| Dec 31, 2024 | 9,166.00 |
| Sep 30, 2024 | 16,659.00 |
| Jun 30, 2024 | 9,933.00 |
| Dec 31, 2023 | 8,225.00 |
| Sep 30, 2023 | 168,269.00 |
| Jun 30, 2023 | 2.28 Mn |
| Mar 31, 2023 | 1.95 Mn |
| Dec 31, 2022 | 2.23 Mn |